Advanced Search
Ongoing Studies
Explore 758 in progress health studies in the Philippines

CATEGORY


SEARCH FILTER

Year
-




Region

Sponsor Classification



  
Results 1 - 10 of 758

In vitro cytotoxicity and binding studies of anti-TAG72 immunoliposomes loaded with Doxorubicin

Implementing Agency
University of the Philippines - Diliman, Institute of Biology
Project Description
The project aims to show that anti-TAG72 immunoliposomes specifically bind then kill TAG72-expressing cells. The immunoliposomes are synthesized from commercial reagents (Dr. Sabido, Project 2). They are then loaded with Doxorubicin. A humanized anti-TAG72 antibody, hCC49 (Dr. Bascos, Project 1), . . .
Date of Registration
20 September 2012
Region
NCR
Sources of Monetary or Material Support
Philippine Council for Health Research and Development, Department of Science and Technology
Health Condition(s) or Problem(s) Studied
Breast cancer

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia

Implementing Agency
PPD Development (S) PTE. LTD.
Project Description
A 3:1 randomization between conivaptan and placebo will be implemented and randomization will be further stratified in a 1:1:2 ratio for age groups: 2-5 years, 6-10 years, and 11-17 years. Subjects will need to remain hospitalized for the 48-hour Treatment Period through Hour 96 (Day 4). There wi . . .
Cooperating Sponsor
Astellas Pharma Europe B.V.
Date of Registration
10 December 2012
Region
NCR
Sources of Monetary or Material Support
Astellas Pharma Europe B.V.
Primary Outcomes
Mean change from baseline to Hour 48 in serum sodium as compared to placebo [ Time Frame: Baseline and Hour 48 ]
Health Condition(s) or Problem(s) Studied
The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of intravenous conivaptan in pediatric subjects with abnormally low concentration of sodium in blood.

Study to evaluate over a prolonged period of time, the safety and the efficacy of a treatment with Reslizumab (at a dose of 3mg/kg) for patients suffering from eosinophilic asthma who completed a prior Cephalon-sponsored study in eosinophilic asthma.

Implementing Agency
PPD Development (S) PTE. LTD.
Project Description
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma, as assessed by the following: • adverse events throughout the study • clinical la . . .
Cooperating Sponsor
Teva Branded Pharmaceutical Products R & D, Inc.
Date of Registration
17 January 2013
Region
NCR
Sources of Monetary or Material Support
Teva Branded Pharmaceutical Products R & D, Inc.
Primary Outcomes
The safety of reslizumab will be assessed throughout the study by evaluating adverse events, clinical laboratory test results, vital signs measurements, brief physical examination findings, concomitant medication usage, and antibodies to reslizumab (immunogenicity) as follows: • Adverse event . . .
Health Condition(s) or Problem(s) Studied
Treatment for patients with eosinophilic asthma

A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first-line therapy in postmenopausal subjects with hormone receptor positive, her2-positive metastatic breast cancer (mbc) who have received trastuzumab and endocrine therapy in the neo/adjuvant setting

Implementing Agency
PPD Development (S) PTE. LTD.
Project Description
This is a Phase III, randomized, open-label, multi-center, three arm study of lapatinib plus trastuzumab plus an aromatase inhibitor (AI), trastuzumab plus an AI, or lapatinib plus an AI to evaluate the efficacy and safety of these regimens as first-line therapy in postmenopausal subjects with hormo . . .
Cooperating Sponsor
GlaxoSmithKline USA
Date of Registration
10 December 2012
Region
NCR
Sources of Monetary or Material Support
GlaxoSmithKline USA
Primary Outcomes
Overall survival of lapatinib/trastuzumab/aromatase inhibitor (AI) combination vs. trastuzumab/AI combination [ Time Frame: approximately 6 years ]
Health Condition(s) or Problem(s) Studied
Breast Cancer

A Study to Investigate How Effective and Safe Solifenacin Liquid Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug (LION)

Implementing Agency
PPD Development (S) PTE. LTD.
Project Description
Solifenacin succinate as a tablet formulation is already on the market for the treatment of symptoms of overactive bladder in adults. For the use in children and adolescent patients a new formulation of solifenacin has been developed. This study will investigate the effect and safety of solifenacin . . .
Cooperating Sponsor
Astellas Pharma Europe B.V.
Date of Registration
19 November 2012
Region
NCR
Sources of Monetary or Material Support
Astellas Pharma Europe B.V.
Primary Outcomes
Change from baseline to EoT (final visit) in mean volume voided per micturition [ Time Frame: Baseline and Week 12 ] The mean voided volume will be determined using the patient diary data of two days (e.g., during the weekend).
Health Condition(s) or Problem(s) Studied
Overactive Bladder

A study to investigate how safe and effective solifenacin fluid is in treating children/adolescents with symptoms of overactive bladder (OAB) who completed study 905-CL-076 (LEOPARD)

Implementing Agency
PPD Development (S) PTE. LTD.
Project Description
This is a 40-week study to investigate how safe and effective solifenacin solution is in treating children/adolescents with symptoms of overactive bladder (OAB) who completed study 905-CL-076. To measure the efficacy of the treatment the patient will complete a 7-day patient diary prior to every vis . . .
Cooperating Sponsor
Astellas Pharma Europe B.V.
Date of Registration
19 November 2012
Region
NCR
Sources of Monetary or Material Support
Astellas Pharma Europe B.V.
Primary Outcomes
Incidence and severity of adverse events [ Time Frame: Week 12 to Week 52 (End of study) ]
Health Condition(s) or Problem(s) Studied
Overactive Bladder

Anti-Inflammatory Constituent(s) from Moringa oleifera Lam. Leaves

Implementing Agency
University of the Philippines - Diliman, Institute of Chemistry
Project Description
Isolation and identification of the anti-inflammatory constituent/s from M. oleifera is a two-pronged project that may lead to lead compounds that can be developed into an anti-inflammatory drug and/or herbal product that is chemically standardized.
Date of Registration
06 November 2012
Region
NCR
Sources of Monetary or Material Support
Philippine Council for Health Research and Development, Department of Science and Technology
Health Condition(s) or Problem(s) Studied
inflammation related diseases

Development and Pilot Testing of a Distal Targeting Device

Implementing Agency
Orthopaedic International, Inc.
Project Description
This project aims to develop a targeting device for distal locking of intramedullary nails without using X-rays. The device will use a patent-pending sensor system to detect the location of the distal screw holes. Design improvements and system accuracy will be investigated, and pilot runs will cond . . .
Date of Registration
29 October 2012
Region
Region IV-A
Sources of Monetary or Material Support
Philippine Council for Health Research and Development, Department of Science and Technology
Health Condition(s) or Problem(s) Studied
Fracture fixation

Studies on Selected Medicinal Plants in Mindanao

Implementing Agency
Mindanao State University - Iligan Institute of Technology, College of Science and Mathematics
Project Description
This project is part of the first phase of a program which ultimately aims to produce herbal preparations or pure therapeutic drug leads sourced out from medicinal plants found in Mindanao. The first phase of this program is exploratory and holistic in nature in the sense t . . .
Date of Registration
08 November 2012
Region
Region X
Sources of Monetary or Material Support
Philippine Council for Health Research and Development, Department of Science and Technology
Health Condition(s) or Problem(s) Studied
cancer, infectious diseases including MRSA, TB and malaria

Using the e-Health Platform for Stakeholder Convergence and Public Advocacy in Support of the Drug Discovery and Development Program (DDDP)

Implementing Agency
Ateneo de Manila University, Institute of Philippine Culture
Project Description
This project aims to redevelop the PCHRD's eHealth Philippines platform and to utilize the platform to facilitate stakeholder convergence and public advocacy in support for the Drug Discovery and Development Program (DDDP ) of PCHRD towards broader research partnerships and collaboration. In achie . . .
Date of Registration
25 January 2013
Region
NCR
Sources of Monetary or Material Support
Philippine Council for Health Research and Development, Department of Science and Technology
Health Condition(s) or Problem(s) Studied
Health Information System; Medicinal Plant Research

Results 1 - 10 of 758
Loading…
©2021 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date